The new regulation would allow health insurance companies to conclude exclusive discount agreements with individual manufacturers. The result would be dangerous economic pressure on suppliers of biosimilars, which often have to be produced at great expense and to the highest quality standards. The associations criticise the fact that proven cost-saving instruments are already generating billions and that a further price focus is not only unnecessary but also dangerous. The consequences would be supply bottlenecks, a lack of traceability in the event of side effects and unsettled patients.
The industry sees the implementation of a law from 2019 as a political mistake, as it is long outdated. The pandemic and the tense geopolitical situation have shown how important production sites in Europe are. Automatic substitution threatens to jeopardise this progress and jeopardise technological sovereignty. The industry's message is clear. If you want to secure supply, you must not cut corners.
News from "BIO Deutschland" from 13 June 2025
